CD40 - CD40 molecule Gene
Also Known as TNFRSF5
Species: Bos taurus
Gene Type: protein coding
Gene ID: 286849
CD40 Products (1)
| mRNA | Protein | Name |
|---|---|---|
| NM_001105611.2 | NP_001099081.1 | tumor necrosis factor receptor superfamily member 5 precursor |
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
tumor necrosis factor receptor superfamily member 5 |
|
|
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
Bioactive MoleculesInhibitory Antibodies
(1)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-P9950 | Omalizumab | Inhibitor | 99.70% | Unkown |
Clinical Phase
Bioactive Molecules
(2)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase |
|---|---|---|---|---|
| HY-B1618 | Corticosterone | Agonist | 99.77% | Phase 3 |
| HY-N6664 | Gum arabic | / | Phase 3 |
Bioactive MoleculesInhibitory Antibodies
(22)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase |
|---|---|---|---|---|
| HY-P99625 | Frexalimab | Inhibitor | 99.00% | Phase 3 |
| HY-P99845 | Dazodalibep | 99.0% | Phase 3 | |
| HY-P99842A | Dapirolizumab | Inhibitor | 99.66% | Phase 3 |
| HY-P99046 | Selicrelumab | Agonist | 99.29% | Phase 2 |
| HY-P99315 | Ruplizumab | Inhibitor | 99.84% | Phase 2 |
| HY-P99742 | Mitazalimab | Inhibitor | 99.23% | Phase 2 |
| HY-P99670 | Iscalimab | Inhibitor | 99.64% | Phase 2 |
| HY-P99049 | Sotigalimab | Agonist | 98.90% | Phase 2 |
| HY-P990726 | Abiprubart | 99.00% | Phase 2 | |
| HY-P99257 | Bleselumab | Inhibitor | 98.97% | Phase 2 |
| HY-P99701 | Letolizumab | Inhibitor | 98.32% | Phase 2 |
| HY-P99167 | Lucatumumab | Inhibitor | ≥99.0% | Phase 2 |
| HY-P99015 | Dacetuzumab | Inhibitor | 95.37% | Phase 2 |
| HY-P99821 | Ravagalimab | Inhibitor | 99.31% | Phase 2 |
| HY-P99572 | Tecaginlimab | Inhibitor | 99.00% | Phase 2 |
| HY-P991525 | 2141-V11 | Agonist | 98.00% | Phase 2 |
| HY-P991510 | CDX-1140 | Agonist | / | Phase 2 |
| HY-P991554 | FFP-104 | Modulator | / | Phase 2 |
| HY-P991556 | TQB2916 | Agonist | / | Phase 2 |
| HY-P991921 | TNX-1500 | Inhibitor | / | Phase 2 |
| HY-P99325 | Toralizumab | Inhibitor | 99.57% | Phase 1 |
| HY-P991666 | BMS-986090 | Inhibitor | / | Phase 1 |
Pre-clinical Phase
Bioactive Molecules
(37)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-122663A | BIO8898 | Inhibitor | 98.77% | Unkown |
| HY-120323 | DRI-C21045 | Inhibitor | 98.11% | Unkown |
| HY-110247 | TRAF-STOP inhibitor 6877002 | Inhibitor | 99.67% | Unkown |
| HY-148980A | Polyinosinic acid sodium | 91.5% | Unkown | |
| HY-154821A | DRI-C21041 DIEA | Inhibitor | 99.07% | Unkown |
| HY-131968 | BMS-986202 | Inhibitor | 99.29% | Unkown |
| HY-153345 | Glucocorticoid receptor agonist-1 phosphate(2,6-difluoro) Ala-Ala-Br | Agonist | 99.67% | Unkown |
| HY-49382 | Fluocinolone acetonide 3-benzylaniline | 99.93% | Unkown | |
| HY-154822 | DRI-C25441 | Inhibitor | 99.53% | Unkown |
| HY-118922 | IW927 | Inhibitor | 99.23% | Unkown |
| HY-152121 | Glucocorticoid receptor agonist-1 phosphate Ala-Ala-Mal | Agonist | 95.68% | Unkown |
| HY-122663 | (Rac)-BIO8898 | Inhibitor | 98.03% | Unkown |
| HY-16668 | Tyrphostin A1 | Inhibitor | 98.96% | Unkown |
| HY-125025 | SMI 6860766 | Inhibitor | / | Unkown |
| HY-154821 | DRI-C21041 | Inhibitor | / | Unkown |
| HY-D1236 | Fluorescent brightener 71 | Inhibitor | / | Unkown |
| HY-P10399 | KGYY15 | Inhibitor | 99.19% | Unkown |
| HY-148980 | Polyinosinic acid | / | Unkown | |
| HY-143410 | Anti-inflammatory agent 16 | Inhibitor | / | Unkown |
| HY-148459 | ATAC21 | / | Unkown | |
| HY-171590 | SIK2-IN-3 | Inhibitor | / | Unkown |
| HY-179701 | NIK-IN-3 | Inhibitor | / | Unkown |
| HY-D1124 | Mordant brown 1 | / | Unkown | |
| HY-D3334 | PE-CF594 | / | Unkown | |
| HY-P10937 | AQP4 (205-215) | / | Unkown | |
| HY-P10937A | AQP4 (205-215) TFA | / | Unkown | |
| HY-RS02246 | CD40 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS02247 | CD40LG Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-120471 | AM-0687 | Inhibitor | / | Unkown |
| HY-168384 | M04 | / | Unkown | |
| HY-174737 | Human CD40LG mRNA | / | Unkown | |
| HY-174738 | Human CD40 mRNA | / | Unkown | |
| HY-400878 | Glucocorticoid receptor agonist-1 phosphate Gly-Glu-Mal | Agonist | 99.86% | Unkown |
| HY-RS16527 | Cd40 Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS17669 | Cd40lg Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS22958 | Cd40 Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS24130 | Cd40lg Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
Bioactive MoleculesInhibitory Antibodies
(19)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-P990680 | Anti-Mouse CD40 Antibody (FGK4.5/FGK45) | Inhibitor | 98.35% | Unkown |
| HY-P990083 | Tegoprubart | Inhibitor | 99.86% | Unkown |
| HY-P990134 | Anti-Mouse CD40L/CD154 Antibody (MR-1) | Inhibitor | 99.62% | Unkown |
| HY-P990860 | Anti-CD40 Antibody (G28.5) | Inhibitor | 95.00% | Unkown |
| HY-P990133 | Anti-Monkey/Human CD40L/CD154 Antibody (5C8) | Inhibitor | 95.00% | Unkown |
| HY-P990111 | BMS-986325 (anti-CD40) | Inhibitor | 99.84% | Unkown |
| HY-P991513 | BI-655064 | Inhibitor | 98.56% | Unkown |
| HY-P99321 | Teneliximab | Inhibitor | ≥99.0% | Unkown |
| HY-P991126 | Ciltistotug | Ligand | 95.376% | Unkown |
| HY-P99663 | Inezetamab | Inhibitor | 99.77% | Unkown |
| HY-P990269 | Anti-Mouse CD40L/CD154 (LALA-PG) Antibody (MR-1) | Inhibitor | 95.00% | Unkown |
| HY-P991086 | MGD010 | Inhibitor | 99.06% | Unkown |
| HY-P990270 | Anti-Mouse CD40L/CD154 (D265A) Antibody (MR-1) | / | Unkown | |
| HY-P991460 | Sym029 | Agonist | / | Unkown |
| HY-P991555 | XmAb5485 | Inducer | / | Unkown |
| HY-P991557 | ABI793 | Inhibitor | / | Unkown |
| HY-P991918 | KHK2840 | Agonist | / | Unkown |
| HY-P991919 | SBT-040 | / | Unkown | |
| HY-P992408 | MEDI-5083 | / | Unkown |